N@N

STERIS Corporation to Announce Fiscal 2011 First Quarter Earnings on August 3, 2010

^{Published on 2010-07-20 05:00:44 - Market Wire}
 

MENTOR, Ohio--([ BUSINESS WIRE ])--STERIS Corporation (NYSE: STE) today announced that it will issue its fiscal 2011 first quarter earnings before the market opens on August 3, 2010, followed by a conference call at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at [ www.steris-ir.com ] or via phone by dialing 1-800-369-8428 in the United States and Canada, or 1-773-799-3378 internationally, then referencing the password aSTERISa.

For those unable to listen to the conference call live, a replay will be available from 12:00 p.m. Eastern time on August 3, 2010 until 5:00 p.m. Eastern time on August 17, either over the Internet at [ www.steris-ir.com ] or via phone by calling 1-866-415-3316 in the United States and Canada, or 1-203-369-0695 internationally.

About STERIS

The mission of STERIS Corporation is to provide a healthier today and safer tomorrow through knowledgeable people and innovative infection prevention, decontamination and health science technologies, products and services. The Company has approximately 5,000 dedicated employees around the world working together to supply a broad array of solutions by offering a combination of equipment, consumables and services to healthcare, pharmaceutical, industrial and government customers. The Company is listed on the New York Stock Exchange under the symbol STE. For more information, visit [ www.steris.com ].

The news release and the referenced conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to the Company or its industry or products that are intended to qualify for the protections afforded aforward-looking statementsa under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date of this report, and may be identified by the use of forward-looking terms such as amay,a awill,a aexpects,a abelieves,a aanticipates,a aplans,a aestimates,a aprojects,a atargets,a aforecasts,a aoutlook,a apotential,a aconfidence,a aimprove,a aoptimistic,a acomfortable,a atrenda, and aseeks,a or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals, or the application or interpretation thereof. Other risk factors are described in the Companya™s Form 10-K and other securities filings. Many of these important factors are outside STERISa™s control. No assurances can be provided as to any outcome from litigation, regulatory action, administrative proceedings, government investigations, warning letters, cost reductions, business strategies, earnings and revenue trends, expense reduction or other future financial results. Reference in the release or elsewhere to the Consent Decree, Transition Plan or other program, or products are summaries only and do not alter or modify the specific terms of the Consent Decree, Transition Plan or other program or product clearance or literature.Consult product labeling for specific product information and indications for use.Unless legally required, the Company does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a)the potential for increased pressure on pricing that leads to erosion of profit margins, (b)the possibility that market demand will not develop for new technologies, products or applications, or the Companya™s business initiatives will take longer, cost more or produce lower benefits than anticipated, (c)the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation previously disclosed FDA warning letters, government investigations, the December3, 2009 or February 22, 2010 FDA notices, the Consent Decree, Transition Plan or Rebate Program or other requirements or standards, may delay, limit or prevent new product introductions, affect the production and marketing of existing products, or otherwise affect Company performance, results, prospects, or value, (d)the potential of international unrest or effects of fluctuations in currencies, tax assessments or rates, raw material costs, benefit or retirement plan costs, or other regulatory compliance costs, (e)the possibility of reduced demand, or reductions in the rate of growth in demand, for the Companya™s products and services, (f)the possibility that anticipated growth, cost savings or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with the Companya™s business, industry or initiatives including, without limitation, the Consent Decree, the transition to the new liquid chemical sterilant processing system, or those matters described in the Companya™s Form 10-K, may adversely impact Company performance, results, prospects, or value, (g)the effect of the contraction in credit availability, as well as the ability of our customers and suppliers to adequately access the credit markets when needed, and (h)those risks described in our Annual Report on Form 10-K for the year ended March31, 2010.